Treatment of Endometriosis with Gn-Rh Agonist Triptorelin: A Multicenter Study
A multicenter trial was carried out to evaluate the safety and efficacy of long acting preparation of Triptorelin-3.75 mg. (Decapeptlyl-Ferring/Erkim-Sweden) for the treatment of endometriosis. A total of 110 patients from 13 institutions with stage ll or higher endometriosis scores were included in the study; 105 of them completed the therapy. Patients underwent a 6-month course of monthly intramuscular injections during which changes in endometriosis symptoms, in biochemical, hematological, hormonal parameters and bone metabolism were evaluated. During the initial laparoscopy peritoneal implants were untouched; whereas of the 46 endometriomas encountered, they were either untouched (n: 13) or a surgical procedure [drainage(n: 23) fulguration (n: 3) cystectomy (n: 7)] was performed. At the end of the treatment, a second-look laparoscopy was performed (n: 93) to determine the efficacy of treatment on endometriotic implants. Initially 64% of patients complained of pelvic pain which dropped to 32% at the end of the treatment. Total AFS score, implants score, and implants score excluding endometriomas dropped significanly (p
Endometriosis, gonadotropin releasing hormone agonist, Triptorelin, ovarian endometrioma, laparoscopy.
GÖKMEN, 0ya and UĞUR, Mustafa (1996) "Treatment of Endometriosis with Gn-Rh Agonist Triptorelin: A Multicenter Study," Turkish Journal of Medical Sciences: Vol. 26: No. 3, Article 9. Available at: https://journals.tubitak.gov.tr/medical/vol26/iss3/9